UBS Group’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.89M Buy
1,373,947
+758,545
+123% +$4.23M ﹤0.01% 3892
2025
Q4
$5.51M Sell
615,402
-292,699
-32% -$1.81M ﹤0.01% 3925
2025
Q3
$3.36M Buy
908,101
+434,162
+92% +$1.18M ﹤0.01% 4447
2025
Q2
$924K Sell
473,939
-397,753
-46% -$828K ﹤0.01% 5512
2025
Q1
$1.53M Sell
871,692
-979,001
-53% -$2.23M ﹤0.01% 4916
2024
Q4
$4.92M Buy
1,850,693
+1,385,584
+298% +$3.57M ﹤0.01% 3869
2024
Q3
$1.07M Buy
465,109
+65,526
+16% +$200K ﹤0.01% 4590
2024
Q2
$1.17M Sell
399,583
-24,219
-6% -$73.9K ﹤0.01% 4274
2024
Q1
$1.54M Buy
423,802
+42,483
+11% +$81.6K ﹤0.01% 4198
2023
Q4
$576K Buy
381,319
+285,713
+299% +$368K ﹤0.01% 4997
2023
Q3
$128K Buy
95,606
+285
+0.3% +$474 ﹤0.01% 5672
2023
Q2
$172K Sell
95,321
-15,033
-14% -$25.6K ﹤0.01% 5589
2023
Q1
$183K Buy
+110,354
New +$224K ﹤0.01% 5452
2022
Q4
Sell
-5,620
Closed -$13K 11009
2022
Q3
$13K Buy
5,620
+3,024
+116% +$8.63K ﹤0.01% 8053
2022
Q2
$8K Buy
2,596
+2,560
+7,111% +$11.2K ﹤0.01% 8327
2022
Q1
$0 Sell
36
-473
-93% -$2.66K ﹤0.01% 10693
2021
Q4
$4K Buy
509
+422
+485% +$3.88K ﹤0.01% 9534
2021
Q3
$1K Buy
87
+20
+30% +$181 ﹤0.01% 9214
2021
Q2
$1K Sell
67
-1,996
-97% -$22.8K ﹤0.01% 9171
2021
Q1
$22K Sell
2,063
-769
-27% -$8.6K ﹤0.01% 7293
2020
Q4
$33K Buy
+2,832
New +$29.5K ﹤0.01% 6558

Other funds holding NUVB

UBS Group's NUVB Position: Q1 2026 in Review

UBS Group increased its Nuvation Bio (NUVB) stake by 123% in Q1 2026, buying an estimated $4.23M and bringing the position to 1,373,947 shares worth $5.89M. The position accounts for ﹤0.01% of the portfolio, ranked #3892.

UBS Group first reported a position in NUVB in Q4 2020 and has held it in 21 quarters since. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • UBS Group held 1,373,947 shares of Nuvation Bio worth $5.89M as of Q1 2026.
  • UBS Group bought 758,545 Nuvation Bio shares in Q1 2026, an estimated $4.23M.
  • Nuvation Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3892 holding.
  • UBS Group first reported a position in Nuvation Bio in Q4 2020 and has held it in 21 quarters since.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.